Literature DB >> 15857248

Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system.

Lang Li1, Huidong Shi, Constantin Yiannoutsos, Tim Hui-Ming Huang, Kenneth P Nephew.   

Abstract

To fully elucidate the functional relationship between DNA methylation and histone hypoacetylation in gene silencing, we have developed an integrated "triple" microarray system that allows us to begin to decipher the influence of epigenetic hierarchies on the regulation of gene expression in cancer cells. Our hypothesis is that in the promoter region of a silenced gene, reversal of two epigenetic factors (i.e., DNA demethylation and/or histone hyperacetylation) is highly correlated with gene reexpression after treatment of the human epithelial ovarian cancer cell line CP70 with the drug combination 5-aza-2'-deoxycytidine (DAC), a demethylating agent, and trichostatin A (TSA), an inhibitor of histone deacetylases. To estimate the posterior probabilities for genes with altered expression, DNA methylation and histone acetylation status measured with a triple-microarray system, we have employed an established empirical Bayes model. Two methods have been proposed to test our hypothesis that DNA demethylation and histone hyperacetylation are highly correlated among those up-regulated genes. One method follows a weighted least squares regression, while the other is derived from a chi-square statistic. The data derived by these approaches, which have been further verified through bootstrap analyses, support the proposed epigenetic correlation (p-values are less than 0.001). Further simulations suggest that even if the constant variance and normality assumptions do not hold, the power of those two tests is robust.

Entities:  

Mesh:

Year:  2005        PMID: 15857248     DOI: 10.1089/cmb.2005.12.370

Source DB:  PubMed          Journal:  J Comput Biol        ISSN: 1066-5277            Impact factor:   1.479


  10 in total

Review 1.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

2.  Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents.

Authors:  Yaping Hou; Fanghua Wang; Linping Cheng; Tao Luo; Jie Xu; Huaqiao Wang
Journal:  Neurosci Bull       Date:  2016-08-13       Impact factor: 5.203

3.  A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.

Authors:  Claudia Arce; Carlos Pérez-Plasencia; Aurora González-Fierro; Erick de la Cruz-Hernández; Alma Revilla-Vázquez; Alma Chávez-Blanco; Catalina Trejo-Becerril; Enrique Pérez-Cárdenas; Lucia Taja-Chayeb; Enrique Bargallo; Patricia Villarreal; Teresa Ramírez; Teresa Vela; Myrna Candelaria; Maria F Camargo; Elizabeth Robles; Alfonso Dueñas-González
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

4.  Hydralazine target: from blood vessels to the epigenome.

Authors:  Claudia Arce; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Myrna Candelaria; Alfonso Dueñnas-Gonzalez
Journal:  J Transl Med       Date:  2006-02-28       Impact factor: 5.531

5.  Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

Authors:  Carlos Perez-Plasencia; Alfonso Duenas-Gonzalez
Journal:  Mol Cancer       Date:  2006-07-10       Impact factor: 27.401

6.  Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.

Authors:  Alma Chavez-Blanco; Carlos Perez-Plasencia; Enrique Perez-Cardenas; Claudia Carrasco-Legleu; Edgar Rangel-Lopez; Blanca Segura-Pacheco; Lucia Taja-Chayeb; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Myrna Candelaria; Gustavo Cabrera; Alfonso Duenas-Gonzalez
Journal:  Cancer Cell Int       Date:  2006-01-31       Impact factor: 5.722

7.  The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.

Authors:  Erick de la Cruz-Hernández; Enrique Pérez-Cárdenas; Adriana Contreras-Paredes; David Cantú; Alejandro Mohar; Marcela Lizano; Alfonso Dueñas-González
Journal:  Virol J       Date:  2007-02-26       Impact factor: 4.099

8.  Empirical bayes model comparisons for differential methylation analysis.

Authors:  Mingxiang Teng; Yadong Wang; Seongho Kim; Lang Li; Changyu Shen; Guohua Wang; Yunlong Liu; Tim H M Huang; Kenneth P Nephew; Curt Balch
Journal:  Comp Funct Genomics       Date:  2012-08-22

9.  A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology.

Authors:  Weixing Feng; Yunlong Liu; Jiejun Wu; Kenneth P Nephew; Tim H M Huang; Lang Li
Journal:  BMC Genomics       Date:  2008-09-16       Impact factor: 3.969

10.  Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.

Authors:  Fu-Fen Yin; Ning Wang; Xiao-Ning Bi; Xiao Yu; Xiao-Hui Xu; You-Lin Wang; Cheng-Quan Zhao; Bing Luo; Yan-Kui Wang
Journal:  Virol J       Date:  2016-04-05       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.